MENU
+Compare
PTGX
Stock ticker: NASDAQ
AS OF
Apr 2, 04:59 PM (EDT)
Price
$48.16
Change
+$1.29 (+2.75%)
Capitalization
2.88B

PTGX Protagonist Therapeutics Forecast, Technical & Fundamental Analysis

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs... Show more

Industry: #Biotechnology
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for PTGX with price predictions
Apr 01, 2025

PTGX in upward trend: price rose above 50-day moving average on March 03, 2025

PTGX moved above its 50-day moving average on March 03, 2025 date and that indicates a change from a downward trend to an upward trend. In of 29 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for PTGX crossed bullishly above the 50-day moving average on March 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for PTGX moved above the 200-day moving average on March 20, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +5 3-day Advance, the price is estimated to grow further. Considering data from situations where PTGX advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PTGX moved out of overbought territory on March 17, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on March 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PTGX as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PTGX turned negative on March 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PTGX broke above its upper Bollinger Band on March 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PTGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.261) is normal, around the industry mean (13.458). P/E Ratio (11.083) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (7.022) is also within normal values, averaging (251.391).

View a ticker or compare two or three
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PTGX is expected to report earnings to fall 103.24% to -6 cents per share on April 30

Protagonist Therapeutics PTGX Stock Earnings Reports
Q1'25
Est.
$-0.06
Q4'24
Beat
by $1.79
Q3'24
Beat
by $0.04
Q2'24
Beat
by $0.10
Q1'24
Beat
by $2.07
The last earnings report on February 21 showed earnings per share of $1.98, beating the estimate of 19 cents. With 501.93K shares outstanding, the current market capitalization sits at 2.88B.
A.I. Advisor
published General Information

General Information

a developer of disulfide-rich peptides

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
7707 Gateway Boulevard
Phone
+1 510 474-0170
Employees
112
Web
https://www.protagonist-inc.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RERBX52.420.38
+0.73%
American Funds Europacific Growth R2
RRSRX29.340.12
+0.41%
Russell Inv Global Real Estate Secs R6
AASCX29.220.03
+0.10%
Thrivent Mid Cap Stock A
SLGFX18.87N/A
N/A
SEI Large Cap Index F (SIMT)
DCSVX10.38N/A
N/A
Dunham Small Cap Value C

PTGX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with CKPT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then CKPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
-3.06%
CKPT - PTGX
47%
Loosely correlated
N/A
DNLI - PTGX
41%
Loosely correlated
-9.60%
TRVI - PTGX
40%
Loosely correlated
-4.45%
ZYME - PTGX
39%
Loosely correlated
-2.43%
ORMP - PTGX
37%
Loosely correlated
-0.47%
More